Improving Health Care Productivity Means ‘Locking Arms With Providers’
Philips is looking beyond COVID-19 and to building more partnership-based relationships in health care delivery
Royal Philips would not routinely invest 10% of its sales in R&D without working with providers to discover their precise needs, says CEO Frans van Houten.
You may also be interested in...
Philips is already the leader in hospital patient monitoring and adding BioTelemetry will make it also the top provider of ambulatory cardiac diagnostics and monitoring systems.
How quickly health care delivery returns to pre-COVID-19 routines is the million-dollar question. With coronavirus volatility still a worrying reality and the burden of chronic care ever present, medtech companies that partner with provider systems must ensure they are covering all the bases. For Royal Philips’ Roy Jakobs, this means delivering on the promises of connected care.
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.